Cryoport (MM) (NASDAQ:CYPT)
Historical Stock Chart
From May 2019 to May 2024
Calypte Biomedical to File Form 8K
ALAMEDA, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Calypte Biomedical
Corporation (BULLETIN BOARD: CYPT) , the developer and marketer of the only two
FDA approved HIV-1 antibody tests for use with urine samples, announced today
that it expects to file Form 8K with the Securities and Exchange Commission. The
filing will contain copies of the letter of intent it recently announced with
WorldVision Africa in connection with a proposed order for Kenya and the
approval letter for Kenya signed by Dr. Jack Nyamongo, Director of the Kenyan
National Laboratory. Also will be included in the 8K is a press releases dated
October 17th announcing that Calypte's Urine Based HIV Test Receives Approval
from the Ministry of Health. The filings will be available at
http://www.freeedgar.com/.
The company knows of no change in its business condition or prospects that would
account for the volatility in its stock today.
About Calypte Biomedical:
Calypte Biomedical Corporation, headquartered in Alameda, California, is a
public healthcare company dedicated to the development and commercialization of
urine-based diagnostic products and services for Human Immunodeficiency Virus
Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases.
Calypte's tests include the screening EIA and supplemental Western Blot tests,
the only two FDA-approved HIV-1 antibody tests that can be used on urine
samples, as well as an FDA-approved serum HIV-1 antibody Western Blot test. The
company believes that accurate, non-invasive urine-based testing methods for HIV
and other infectious diseases may make important contributions to public health
by helping to foster an environment in which testing may be done safely,
economically, and painlessly. Calypte markets its products in countries
worldwide through international distributors and strategic partners. Current
product labeling including specific product performance claims can be found at
http://www.calypte.com/.
Statements in this press release that are not historical facts are
forward-looking statements within the meaning of the Securities Act of 1933, as
amended. Those statements include statements regarding the intent, belief or
current expectations of the Company and its management. Such statements reflect
management's current views, are based on certain assumptions and involve risks
and uncertainties. Actual results, events, or performance may differ materially
from the above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not limited to,
our ability to obtain additional financing and access funds from our existing
financing arrangements that will allow us to continue our current and future
operations and whether demand for our product and testing service in domestic
and international markets will continue to expand. The Company undertakes no
obligation to publicly update these forward-looking statements to reflect events
or circumstances that occur after the date hereof or to reflect any change in
the Company's expectations with regard to these forward-looking statements or
the occurrence of unanticipated events. Factors that may impact the Company's
success are more fully disclosed in the Company's most recent public filings
with the U.S. Securities and Exchange Commission ("SEC"), including its annual
report on Form 10-K for the year ended December 31, 2002 and its subsequent
filings with the SEC.
Investor Relations Contact:
Tim Clemensen
212-843-9337
email:
DATASOURCE: Calypte Biomedical Corporation
CONTACT: Investor Relations - Tim Clemensen, +1-212-843-9337 or
, for Calypte Biomedical Corporation
Web site: http://www.calypte.com/